Subarachnoid Hemorrhage

• 

  Subject Areas on Research

  • A comparison of preference assessment instruments used in a clinical trial: responses to the visual analog scale from the EuroQol EQ-5D and the Health Utilities Index. 
  • A comparison of scoring weights for the EuroQol derived from patients and the general public. 
  • A novel apoE-derived therapeutic reduces vasospasm and improves outcome in a murine model of subarachnoid hemorrhage. 
  • A risk score for in-hospital death in patients admitted with ischemic or hemorrhagic stroke. 
  • An apoE-derived mimic peptide, COG1410, alleviates early brain injury via reducing apoptosis and neuroinflammation in a mouse model of subarachnoid hemorrhage. 
  • An observational pilot study of CSF diversion in subarachnoid haemorrhage. 
  • Aneurysm rupture: lunar cycle, weather, atmospheric pressure, myth or reality? 
  • Aneurysmal subarachnoid hemorrhage in patients under 35-years-old: a single-center experience. 
  • Apolipoprotein E Exerts a Whole-Brain Protective Property by Promoting M1? Microglia Quiescence After Experimental Subarachnoid Hemorrhage in Mice. 
  • Attenuation of cerebral vasospasm after subarachnoid hemorrhage in mice overexpressing extracellular superoxide dismutase. 
  • Bilateral footdrop after treatment of an anterior communicating artery aneurysm: a case report and review of the literature. 
  • CT evaluation of subarachnoid hemorrhage: a practical review for the radiologist interpreting emergency room studies. 
  • Cardiac Dysfunction After Neurologic Injury: What Do We Know and Where Are We Going? 
  • Central nervous system bleeding in hemophiliacs. 
  • Cerebral aneurysms: mechanisms of injury and critical care interventions. 
  • Cerebral blood flow velocity response to magnesium sulfate in patients after subarachnoid hemorrhage. 
  • Cerebral mycotic aneurysm in a child with Down's syndrome: a unique association. 
  • Cerebrospinal fluid atrial natriuretic factor in intracranial disease. 
  • Changing outcome from aneurysmal subarachnoid hemorrhage: another step closer. 
  • Characteristics of nontraumatic subarachnoid hemorrhage in the United States in 2003. 
  • Characteristics, performance measures, and in-hospital outcomes of the first one million stroke and transient ischemic attack admissions in get with the guidelines-stroke. 
  • Comments on "sensitivity of noncontrast cranial computed tomography for the emergency department diagnosis of subarachnoid hemorrhage". 
  • Comparison of techniques for ventriculoperitoneal shunting in 523 patients with subarachnoid hemorrhage. 
  • Comparison of the use of medical resources and outcomes in the treatment of aneurysmal subarachnoid hemorrhage between Canada and the United States. 
  • Continuous and intermittent CSF diversion after subarachnoid hemorrhage: a pilot study. 
  • Continuous cerebral spinal fluid drainage associated with complications in patients admitted with subarachnoid hemorrhage. 
  • Correlation of serum brain natriuretic peptide with hyponatremia and delayed ischemic neurological deficits after subarachnoid hemorrhage. 
  • Costs of vasospasm in patients with aneurysmal subarachnoid hemorrhage. 
  • Diagnostic yield of cerebral angiography in patients with computed tomography-negative, lumbar puncture-positive subarachnoid hemorrhage. 
  • Dissociation between vasospasm and functional improvement in a murine model of subarachnoid hemorrhage. 
  • Dysregulation of oxygen hemodynamic responses to synaptic train stimulation in a rat hippocampal model of subarachnoid hemorrhage. 
  • Economic analysis of tirilazad mesylate for aneurysmal subarachnoid hemorrhage. Economic evaluation of a phase III clinical trial in Europe and Australia. 
  • Effect of 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (Voluven®) on complications after subarachnoid hemorrhage: a retrospective analysis. 
  • Efficacy of multiple intraarterial papaverine infusions for improvement in cerebral circulation time in patients with recurrent cerebral vasospasm. 
  • Endovascular management of cerebral vasospasm following aneurysm rupture: outcomes and predictors in 116 patients. 
  • Endovascular treatment of cerebral vasospasm. 
  • Endovascular treatment of distal intracranial aneurysms with Onyx 18/34. 
  • Estimating country-specific cost-effectiveness from multinational clinical trials. 
  • Evaluation of neonatal intracranial hemorrhage by computerized tomography. 
  • Galbraith Award: simvastatin attenuates experimental cerebral vasospasm and ameliorates serum markers of neuronal and endothelial injury in patients after subarachnoid hemorrhage: a dose-response effect dependent on endothelial nitric oxide synthase. 
  • Hospital case volume is associated with mortality in patients hospitalized with subarachnoid hemorrhage. 
  • Hospitalization and case-fatality rates for subarachnoid hemorrhage in Canada from 1982 through 1991. The Canadian Collaborative Study Group of Stroke Hospitalizations. 
  • Imaging evaluation of the patient with worst headache of life--it's not all subarachnoid hemorrhage. 
  • Impact of ruptured cerebral aneurysm coiling and clipping on the incidence of cerebral vasospasm and clinical outcome. 
  • In-hospital outcomes of aneurysmal subarachnoid hemorrhage associated with cocaine use in the USA. 
  • Influence of stroke subtype on quality of care in the Get With The Guidelines-Stroke Program. 
  • Inhibition of Blood-Brain Barrier Disruption by an Apolipoprotein E-Mimetic Peptide Ameliorates Early Brain Injury in Experimental Subarachnoid Hemorrhage. 
  • Intracranial arterial avulsion during orbital exenteration. 
  • Leukocytosis as an independent risk factor for cerebral vasospasm following aneurysmal subarachnoid hemorrhage. 
  • Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage. 
  • Long-Term Cognitive Deficits After Subarachnoid Hemorrhage in Rats. 
  • Long-term cognitive dysfunction following experimental subarachnoid hemorrhage: new perspectives. 
  • Magnesium neuroprotection is limited in humans with acute brain injury. 
  • Management of post-subarachnoid hemorrhage vasospasm. 
  • Meta-analysis of intracranial hemorrhage in acute coronary syndromes: incidence, predictors, and clinical outcomes. 
  • Mouse model of subarachnoid hemorrhage associated cerebral vasospasm: methodological analysis. 
  • Neurogenic Stunned Myocardium Following Acute Subarachnoid Hemorrhage: Pathophysiology and Practical Considerations. 
  • Neurogenic pulmonary edema during intracranial endovascular therapy. 
  • Neuroprotection in subarachnoid hemorrhage. 
  • Neuroprotective effect of curcumin in an experimental rat model of subarachnoid hemorrhage. 
  • Neuroprotective efficacy from a lipophilic redox-modulating Mn(III) N-Hexylpyridylporphyrin, MnTnHex-2-PyP: rodent models of ischemic stroke and subarachnoid hemorrhage. 
  • Perioperative management of aneurysmal subarachnoid hemorrhage: Part 1. Operative management. 
  • Perioperative management of aneurysmal subarachnoid hemorrhage: Part 2. Postoperative management. 
  • Pharmacologically augmented S-nitrosylated hemoglobin improves recovery from murine subarachnoid hemorrhage. 
  • Physiological and histopathological responses following closed rotational head injury depend on direction of head motion. 
  • Possible role for vascular cell proliferation in cerebral vasospasm after subarachnoid hemorrhage. 
  • Potential implications of Apolipoprotein E in early brain injury after experimental subarachnoid hemorrhage: Involvement in the modulation of blood-brain barrier integrity. 
  • Processed electroencephalogram during donation after cardiac death. 
  • Proteomic biomarker discovery in cerebrospinal fluid for cerebral vasospasm following subarachnoid hemorrhage. 
  • Requisite ischemia for spreading depolarization occurrence after subarachnoid hemorrhage in rodents. 
  • Resource costing for multinational neurologic clinical trials: methods and results. 
  • Reversal of warfarin associated coagulopathy with 4-factor prothrombin complex concentrate in traumatic brain injury and intracranial hemorrhage. 
  • Risk of cerebral vasopasm after subarachnoid hemorrhage reduced by statin therapy: A multivariate analysis of an institutional experience. 
  • Risk of intracranial aneurysms in families with subarachnoid hemorrhage. 
  • Role of vascular mitogens in subarachnoid hemorrhage-associated cerebral vasculopathy. 
  • Serum von Willebrand factor, matrix metalloproteinase-9, and vascular endothelial growth factor levels predict the onset of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. 
  • Simvastatin in subarachnoid haemorrhage: beyond the short-term. 
  • Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage. 
  • Simvastatin reduces vasospasm after aneurysmal subarachnoid hemorrhage: results of a pilot randomized clinical trial. 
  • Simvastatin treatment duration and cognitive preservation in experimental subarachnoid hemorrhage. 
  • Spontaneous delayed migration/shortening of the pipeline embolization device: report of 5 cases. 
  • Spontaneous spinal subarachnoid hemorrhage secondary to spinal aneurysms: diagnosis and treatment paradigm. 
  • Spontaneous vertebral dissection: clinical, conventional angiographic, CT, and MR findings. 
  • Stent-assisted coiling of wide-necked aneurysms in the setting of acute subarachnoid hemorrhage: experience in 65 patients. 
  • Subarachnoid hemorrhage due to isolated spinal artery aneurysm in four patients. 
  • Subarachnoid hemorrhage from intracranial dissecting aneurysm. 
  • Subarachnoid hemorrhage with negative initial catheter angiography: a review of 254 cases evaluating patient clinical outcome and efficacy of short- and long-term repeat angiography. 
  • Synthes Award for Resident Research in Spinal Cord & Spinal Column Injury: Statins for the treatment of neurological injury: a role beyond cholesterol lowering. 
  • Temporal bone fracture. 
  • Temporal changes in glutamate, glutamate transporters, basilar arteries wall thickness, and neuronal variability in an experimental rat model of subarachnoid hemorrhage. 
  • The case for family screening for intracranial aneurysms. 
  • The deleterious effects of methamphetamine use on initial presentation and clinical outcomes in aneurysmal subarachnoid hemorrhage. 
  • The evolution of future directions of neuroendovascular therapy: from clips to coils to? 
  • The new standing guideline committee policy of the American Stroke Association Stroke Council. 
  • The pipeline embolization device: beyond the approved indication. 
  • The relationship of blunt head trauma, subarachnoid hemorrhage, and rupture of pre-existing intracranial saccular aneurysms. 
  • The use of S100B as a biomarker in subarachnoid hemorrhage: clarity in its promise and limits. 
  • The utility of cone beam volume CT in the evaluation of thrombosed intracranial aneurysms in subarachnoid hemorrhage. 
  • The utility of cone beam volume CT in the evaluation of thrombosed intracranial aneurysms in subarachnoid hemorrhage. 
  • The value of CT angiography and transcranial doppler sonography in triaging suspected cerebral vasospasm in SAH prior to endovascular therapy. 
  • Timing of symptomatic vasospasm in aneurysmal subarachnoid hemorrhage: the effect of treatment modality and clinical implications. 
  • Toward a better understanding of temporal patterns of aneurysmal subarachnoid hemorrhage. 
  • Treatment of a basilar trunk perforator aneurysm with the pipeline embolization device: case report. 
  • Treatment of cerebral vasospasm after subarachnoid hemorrhage--a review. 
  • Treatment of complex intracranial aneurysms with a telescoping stent technique. 
  • Treatment outcome of aneurysmal subarachnoid hemorrhage in patients aged 70 years and older. 
  • Use of the peak troponin value to differentiate myocardial infarction from reversible neurogenic left ventricular dysfunction associated with aneurysmal subarachnoid hemorrhage. 
  • Using transcranial Doppler sonography to augment the neurological examination after aneurysmal subarachnoid hemorrhage. 
  • Utility of levetiracetam in patients with subarachnoid hemorrhage. 
  • [Idiopathic subarachnoid hemorrhage; comparison of different bleeding patterns and long-term outcome] 
  • pH-sensitive NMDA inhibitors improve outcome in a murine model of SAH. 
• 

  Keywords of People

  • Curtis, Lesley H., Professor in Population Health Sciences, Medicine, General Internal Medicine
  • James, Michael Lucas, Associate Professor of Anesthesiology, Anesthesiology, Neuroanesthesia
  • Laskowitz, Daniel Todd, Professor of Neurology, Duke Innovation & Entrepreneurship
  • Reed, Shelby Derene, Professor in Population Health Sciences, Duke Science & Society
  • Warner, David Samuel, Distinguished Professor of Anesthesiology, in the School of Medicine, Neurobiology
  • Zhang, Zhiquan, Assistant Professor in Anesthesiology, Anesthesiology